Literature DB >> 33358150

Small Cell Bladder Cancer Response to Second-line and Beyond Checkpoint Inhibitor Therapy: Retrospective Experience.

Jean Hoffman-Censits1, Woonyoung Choi2, Trinity J Bivalacqua2, Philip Pierorazio2, Max Kates2, Kara Lombardo2, Vamsi Parini3, David McConkey2, Edouard J Trabulsi4, Noah Hahn5, Andres Matoso6.   

Abstract

Entities:  

Keywords:  Immunotherapy; Neuroendocrine cancer; Platinum refractory cancer; Upper tract; Variant histology

Mesh：

Substances：

Year:  2020        PMID： 33358150      PMCID： PMC9281535          DOI： 10.1016/j.clgc.2020.10.009

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN： 1558-7673            Impact factor:   3.121


× No keyword cloud information.
  32 in total

1.  Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis.

Authors:  Karin Birkenkamp-Demtröder; Emil Christensen; Iver Nordentoft; Michael Knudsen; Ann Taber; Søren Høyer; Philippe Lamy; Mads Agerbæk; Jørgen Bjerggaard Jensen; Lars Dyrskjøt
Journal:  Eur Urol       Date:  2017-09-27       Impact factor: 20.096

2.  A Surveillance, Epidemiology, and End Results analysis of small cell carcinoma of the bladder: epidemiology, prognostic variables, and treatment trends.

Authors:  Eugene J Koay; Bin S Teh; Arnold C Paulino; E Brian Butler
Journal:  Cancer       Date:  2011-05-12       Impact factor: 6.860

3.  Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.

Authors:  Padmanee Sharma; Margitta Retz; Arlene Siefker-Radtke; Ari Baron; Andrea Necchi; Jens Bedke; Elizabeth R Plimack; Daniel Vaena; Marc-Oliver Grimm; Sergio Bracarda; José Ángel Arranz; Sumanta Pal; Chikara Ohyama; Abdel Saci; Xiaotao Qu; Alexandre Lambert; Suba Krishnan; Alex Azrilevich; Matthew D Galsky
Journal:  Lancet Oncol       Date:  2017-01-26       Impact factor: 41.316

4.  Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer.

Authors:  H Okamoto; K Watanabe; Y Nishiwaki; K Mori; Y Kurita; I Hayashi; M Masutani; K Nakata; S Tsuchiya; H Isobe; N Saijo
Journal:  J Clin Oncol       Date:  1999-11       Impact factor: 44.544

Review 5.  Small-Cell Carcinoma of the Bladder: 20-Year Single-Institution Retrospective Review.

Authors:  Kyungsuk Jung; Pooja Ghatalia; Samuel Litwin; Eric M Horwitz; Robert G Uzzo; Richard E Greenberg; Rosalia Viterbo; Daniel M Geynisman; Alexander Kutikov; Elizabeth R Plimack; Marc C Smaldone; Yu-Ning Wong; Marijo Bilusic
Journal:  Clin Genitourin Cancer       Date:  2016-09-30       Impact factor: 2.872

6.  Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience.

Authors:  Arlene O Siefker-Radtke; Colin P Dinney; Neil A Abrahams; Cesar Moran; Yu Shen; Louis L Pisters; H Barton Grossman; David A Swanson; Randall E Millikan
Journal:  J Urol       Date:  2004-08       Impact factor: 7.450

7.  Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.

Authors:  Primo N Lara; Ronald Natale; John Crowley; Heinz Josef Lenz; Mary W Redman; Jane E Carleton; James Jett; Corey J Langer; J Philip Kuebler; Shaker R Dakhil; Kari Chansky; David R Gandara
Journal:  J Clin Oncol       Date:  2009-04-06       Impact factor: 44.544

8.  First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.

Authors:  Arjun V Balar; Daniel Castellano; Peter H O'Donnell; Petros Grivas; Jacqueline Vuky; Thomas Powles; Elizabeth R Plimack; Noah M Hahn; Ronald de Wit; Lei Pang; Mary J Savage; Rodolfo F Perini; Stephen M Keefe; Dean Bajorin; Joaquim Bellmunt
Journal:  Lancet Oncol       Date:  2017-09-26       Impact factor: 41.316

9.  Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer.

Authors:  Gopa Iyer; Arjun V Balar; Matthew I Milowsky; Bernard H Bochner; Guido Dalbagni; S Machele Donat; Harry W Herr; William C Huang; Samir S Taneja; Michael Woods; Irina Ostrovnaya; Hikmat Al-Ahmadie; Maria E Arcila; Jamie C Riches; Andreas Meier; Caitlin Bourque; Maha Shady; Helen Won; Tracy L Rose; William Y Kim; Brooke E Kania; Mariel E Boyd; Catharine K Cipolla; Ashley M Regazzi; Daniela Delbeau; Asia S McCoy; Hebert Alberto Vargas; Michael F Berger; David B Solit; Jonathan E Rosenberg; Dean F Bajorin
Journal:  J Clin Oncol       Date:  2018-05-09       Impact factor: 44.544

10.  Copy number variations of circulating, cell-free DNA in urothelial carcinoma of the bladder patients treated with radical cystectomy: a prospective study.

Authors:  Armin Soave; Felix K-H Chun; Timo Hillebrand; Michael Rink; Lars Weisbach; Bettina Steinbach; Margit Fisch; Klaus Pantel; Heidi Schwarzenbach
Journal:  Oncotarget       Date:  2017-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.